Many payers are incorporating Fitbit technology into healthcare plans as part of both prevention and clinical treatment programs, hoping that it can help members become healthier and more active, according to Ben Sommers, MBA, vice president of North America Business Development at Fitbit Wellness.
Many payers are incorporating Fitbit technology into healthcare plans as part of both prevention and clinical treatment programs, hoping that it can help members become healthier and more active, according to Ben Sommers, MBA, vice president of North America Business Development at Fitbit Wellness.
Transcript (slightly modified)
What work is Fitbit Group Health doing with payers? Have you run into any barriers?
So, no barriers that we’ve seen today. What’s been really interesting though is, there’s so many possibilities in terms of the clinical programs where Fitbit technology can be a part of an effective treatment program. For example, I was just speaking with a leading health system just yesterday, where their hypothesis is that when it comes to heart health, especially with the advancing features within Fitbit products where we have heart rate monitoring, although we’re not an FDA medically-approved device, can we still be a useful part of a program as it relates to heart health?
One other interesting development that we’re focused on, is there an opportunity for a very large swath of the population, for an entire member base within a health plan, to actually receive Fitbit as part of their plan experience. So maybe you’re not necessarily battling a clinical condition, but just by being a member of that plan, because there’s such high value with helping folks with data, inspiration and guidance to lead a more active, healthy life. If they have this included as part of that plan, there’s actually going to be benefits both for them as the health plan and then certainly in a self-insured environment for the employer.
Inside the Center's MDD Value Model and Its Use of Dynamic Pricing
May 13th 2025Larragem Raines, MS, of the Center for Innovation & Value Research, discusses the organization's major depressive disorder (MDD) open-source value model, dynamic pricing, and the future role of artificial intelligence in care.
Listen
Quantitative Magnetic Resonance Outcomes Suggest Gene Therapy Slows DMD Progression
May 14th 2025Delandistrogene moxeparvovec (Elevidys; Sarepta Therapeutics) appeared to protect muscle from progressive damage in patients with Duchenne muscular dystrophy (DMD) based on muscle quantitative magnetic resonance measures.
Read More
Real-World Data Show Bevacizumab Benefits Only High-Risk Patients With Epithelial Ovarian Cancer
May 13th 2025In line with previous clinical trial findings, real-world data show that bevacizumab improves outcomes in patients with epithelial ovarian cancer and high-risk prognostic factors.
Read More